These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Allele-Specific Mechanisms of Activation of MEK1 Mutants Determine Their Properties. Gao Y; Chang MT; McKay D; Na N; Zhou B; Yaeger R; Torres NM; Muniz K; Drosten M; Barbacid M; Caponigro G; Stuart D; Moebitz H; Solit DB; Abdel-Wahab O; Taylor BS; Yao Z; Rosen N Cancer Discov; 2018 May; 8(5):648-661. PubMed ID: 29483135 [TBL] [Abstract][Full Text] [Related]
3. BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity. Emery CM; Monaco KA; Wang P; Balak M; Freeman A; Meltzer J; Delach SM; Rakiec D; Ruddy DA; Korn JM; Haling J; Acker MG; Caponigro G Mol Cancer Res; 2017 Oct; 15(10):1431-1444. PubMed ID: 28655712 [TBL] [Abstract][Full Text] [Related]
4. V211D Mutation in MEK1 Causes Resistance to MEK Inhibitors in Colon Cancer. Gao Y; Maria A; Na N; da Cruz Paula A; Gorelick AN; Hechtman JF; Carson J; Lefkowitz RA; Weigelt B; Taylor BS; Zhao H; Reis-Filho JS; de Stanchina E; Rosen N; Yao Z; Yaeger R Cancer Discov; 2019 Sep; 9(9):1182-1191. PubMed ID: 31227518 [TBL] [Abstract][Full Text] [Related]
5. Identification of the MEK1(F129L) activating mutation as a potential mechanism of acquired resistance to MEK inhibition in human cancers carrying the B-RafV600E mutation. Wang H; Daouti S; Li WH; Wen Y; Rizzo C; Higgins B; Packman K; Rosen N; Boylan JF; Heimbrook D; Niu H Cancer Res; 2011 Aug; 71(16):5535-45. PubMed ID: 21705440 [TBL] [Abstract][Full Text] [Related]
6. Germline mutations of MEK in cardio-facio-cutaneous syndrome are sensitive to MEK and RAF inhibition: implications for therapeutic options. Senawong T; Phuchareon J; Ohara O; McCormick F; Rauen KA; Tetsu O Hum Mol Genet; 2008 Feb; 17(3):419-30. PubMed ID: 17981815 [TBL] [Abstract][Full Text] [Related]
8. ERK1/2 can feedback-regulate cellular MEK1/2 levels. Hong SK; Wu PK; Karkhanis M; Park JI Cell Signal; 2015 Oct; 27(10):1939-48. PubMed ID: 26163823 [TBL] [Abstract][Full Text] [Related]
9. Allosteric MEK1/2 inhibitors including cobimetanib and trametinib in the treatment of cutaneous melanomas. Roskoski R Pharmacol Res; 2017 Mar; 117():20-31. PubMed ID: 27956260 [TBL] [Abstract][Full Text] [Related]
10. MEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms. Wu PK; Park JI Semin Oncol; 2015 Dec; 42(6):849-62. PubMed ID: 26615130 [TBL] [Abstract][Full Text] [Related]
11. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers. Roskoski R Pharmacol Res; 2018 Sep; 135():239-258. PubMed ID: 30118796 [TBL] [Abstract][Full Text] [Related]
12. MEK1/2 inhibitors in the treatment of gynecologic malignancies. Miller CR; Oliver KE; Farley JH Gynecol Oncol; 2014 Apr; 133(1):128-37. PubMed ID: 24434059 [TBL] [Abstract][Full Text] [Related]
13. Identification of an "Exceptional Responder" Cell Line to MEK1 Inhibition: Clinical Implications for MEK-Targeted Therapy. Gannon HS; Kaplan N; Tsherniak A; Vazquez F; Weir BA; Hahn WC; Meyerson M Mol Cancer Res; 2016 Feb; 14(2):207-15. PubMed ID: 26582713 [TBL] [Abstract][Full Text] [Related]
14. Allosteric modulators of MEK1: drug design and discovery. Shang J; Lu S; Jiang Y; Zhang J Chem Biol Drug Des; 2016 Oct; 88(4):485-97. PubMed ID: 27115708 [TBL] [Abstract][Full Text] [Related]
15. Characterization of a novel mitogen-activated protein kinase kinase 1/2 inhibitor with a unique mechanism of action for cancer therapy. Daouti S; Wang H; Li WH; Higgins B; Kolinsky K; Packman K; Specian A; Kong N; Huby N; Wen Y; Xiang Q; Podlaski FJ; He Y; Fotouhi N; Heimbrook D; Niu H Cancer Res; 2009 Mar; 69(5):1924-32. PubMed ID: 19244124 [TBL] [Abstract][Full Text] [Related]